Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ambien Not Sleepwalking Through Scrutiny; Label Warnings Updated

Executive Summary

Sanofi's sleeping pill has been revised once again in an update that also limits the recommended dosing.

You may also be interested in...



Gender-Based Dosing For Insomnia Drugs Dissected In NEJM

CDER officials explain the rationale behind new labeling on zolpidem-containing immediate- and controlled-release products that halves the recommended dose for women. Labeling changes include a new precaution against next-day driving following use of Sanofi’s Ambien CR.

Rep. Kennedy to join Ambien lawsuit?

Rep. Patrick Kennedy (D-R.I.) says he will check himself into the Mayo Clinic for rehab after he ran into a security barrier in Washington, D.C. May. When Capitol Police picked up the disoriented congressman at 2:45 a.m., he claimed he was headed to the Capitol for a vote. In a statement, Kennedy maintained that he was not under the influence of alcohol at the time of the incident, but admitted to having taken Sanofi-Aventis' insomnia therapy Ambien and Wyeth's antihistamine Phenergan. A recently filed class action lawsuit alleges Sanofi failed to adequately warn patients of risk of sleep walking and eating with Ambien (1"The Pink Sheet" March 20,2006, p. 18)...

Xpovio Avoided Complete Response Letter Through Late-Cycle Submission Of BOSTON Data

After US FDA's Oncologic Drugs Advisory Committee voted to delay approval of Karyopharm's multiple myeloma drug Xpovio, the company submitted some data from the Phase III BOSTON trial, which prompted the FDA to award an accelerated approval for a narrower indication.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS118961

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel